Product
Eureka
For R&D, Eureka makes reading and utilizing patents & technical documents easy.
Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
287 results about "Cardiac disorders" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Cardiovascular disease (CVD) is a collective term for diseases of the heart and blood vessels. The term commonly includes diseases such as coronary heart disease, heart failure, cardiomyopathy, congenital heart disease, peripheral vascular disease and stroke.
Ablation catheters and methods for their use
InactiveUS20050033137A1Reduce riskGood electrical contactDiagnostic recording/measuringSensorsDiseaseCardiac disorders
The present invention relates generally to multifunctional catheters for performing ablation procedures, and more particularly to ablation catheters utilized in the treatment of atrial fibrillation and other cardiac disorders. The present invention eliminates many of the problems associated with previous ablation catheters by providing an ablation treatment not dependent upon continuous lesions.
Owner:RGT UNIV OF MICHIGAN
Cardiac disease treatment and device
A device for treating cardiac disease of a heart having an upper portion and a lower portion divided by an A–V groove, the device including a jacket adapted to be secured to the heart, and a delivery source for the delivery of one or more therapeutic agents to the surface of the heart. The jacket is fabricated from a flexible material defining a volume between an upper and a lower end, the jacket being adapted to be adjusted on the heart to snugly conform to an external geometry of the heart and assume a maximum adjusted volume for the jacket to constrain expansion of the heart beyond the maximum adjusted volume during diastole and permit substantially unimpeded contraction of the heart during systole. As a result of the flexible material, the jacket allows unimpeded diastolic filling of the heart. Also described is a method for treating cardiac disease including surgically accessing the heart, applying the treatment device of the invention, securing the treatment device to the heart, and surgically closing access to the heart while leaving the treatment device on the heart.
Owner:MARDIL
Ablation catheters
The present invention relates generally to multifunctional catheters for performing ablation procedures, and more particularly to ablation catheters utilized in the treatment of atrial fibrillation and other cardiac disorders. The present invention eliminates many of the problems associated with previous ablation catheters by providing an ablation treatment not dependent upon continuous lesions.
Owner:RGT UNIV OF MICHIGAN
Ablation catheters
Owner:RGT UNIV OF MICHIGAN
Composition comprising Xanthoceras sorbifolia extracts, compounds isolated from same, methods for preparing same and uses thereof
ActiveUS20050276872A1Preventing cerebral agingEnhance memoryBiocideSugar derivativesRheumatismCoronary heart disease
This invention provides compositions, methods and process of producing extracts and pure compounds from Xanthoceras sorbifolia. The extract comprises saponins and other constituents including alkaloids, coumarins, saccharides, proteins, polysaccharides, glycosides, tannins, acid, flavonoids and others. The composition can be used for treating cancer and other conditions, such as arthritis, rheumatism, poor circulation, arteriosclerosis, Raynaud's syndrome, angina pectoris, cardiac disorder, coronary heart disease, headache, kidney disorder, and impotence; for improving cerebral functions; or for curing enuresis, frequent micturition, urinary incontinence, dementia, weak intelligence and Alzheimer's disease, autism, brain trauma, Parkinson's, cerebral dysfunctions, and treating arthritis, rheumatism, poor circulation, arteriosclerosis, Raynaud's syndrome, angina pectoris, cardiac disorder, headache, dizziness, kidney disorder. This invention provides compounds of oleanene triterpenoidal saponin in nature with the characteristics that at least one angeloyl group attache to Carbon 21 or / and 22, or / and linked to the sugar. The compounds of the present invention have various pharmaceutical and therapeutic applications.
Owner:PACIFIC ARROW
Selective opioid compounds
ActiveUS20090209569A1Reducing lipid permeability of drugReduce penetrationAntibacterial agentsBiocideDiseaseInterstitial cystitis
The present invention relates to compounds of Formula I or II, or pharmaceutically acceptable salts, esters, or prodrugs thereof:which relates to morphinan compounds useful as μ, δ, and / or κ receptor opioid compounds and pharmaceuticals containing same that may be useful for mediating analgesia, combating drug addiction, alcohol addiction, drug overdose, mental illness, bladder dysfunctions, neurogenic bladder, interstitial cystitis, urinary incontinence, premature ejaculation, inflammatory pain, peripherally mediated and neuropathic pain, cough, lung edema, diarrhea, cardiac disorders, cardioprotection, depression, and cognitive, respiratory, diarrhea, irritable bowel syndrome and gastro-intestinal disorders, immunomodulation, and anti-tumor agents.
Owner:ALKERMES INC
Device and method for treating disorders of the cardiovascular system or heart
ActiveUS20080188904A1Reduce rateReduce high blood pressureElectrotherapyArtificial respirationDiseaseCardiac disorders
A device and method are provided to treat heart failure by stimulating to cause diaphragm contraction.
Owner:RMX
Cardiac Monitoring And Therapy Using A Device For Providing Pressure Treatment Of Sleep Disordered Breathing
A method of using CPAP equipment to sense cardiogenic oscillations in a patient's airflow, and to monitor and treat the patient's cardiac condition. The apparatus diagnoses cardiac morbidity conditions, such as the existence of arrhythmias or other cardiac abnormalities, and influences and optimizes cardiac stroke volume. The apparatus further monitors pulse-transit time, changes in the heart pre-ejection period, and the duration of the cardiac cycle.
Owner:RESMED LTD
Methods for treating cardiac arrhythmia and preventing death due to cardiac arrhythmia using ngf antagonists
InactiveUS20060147450A1Treating and preventing and reducing incidence of NGF-associatedPrevent and reduce incidenceImmunoglobulins against growth factorsAntibody ingredientsCardiac disordersCardiac arrhythmia
This invention relates to the field of cardiac disease. More specifically, the invention relates to methods using an NGF antagonist for treating and preventing cardiac arrhythmia and methods of preventing death due to cardiac arrhythmia.
Owner:RINAT NEUROSCI CORP
System and method for diagnosing and treating long qt syndrome
InactiveUS20080255464A1Easy to identifySimple methodElectrocardiographyAuscultation instrumentsSystoleCardiac cycle
A system for diagnosing Long QT Syndrome (LQTS) derives a QT / QS2 ratio from an electrical systole (QT) and a mechanical systole (QS2) to detect a prolonged QT interval in a patient's cardiac cycle. A processor acquires the systoles from a microphone and chest electrodes, calculates the QT / QS2 ratio, and outputs the result to a display. The processor may compare the QT / QS2 ratio to a threshold value stored in memory for diagnosing LQTS in the patient. A user interface provides for programming, set-up, and customizing the display. A mode selector allows the system to operate alternatively as a phonocardiograph, a 12 lead electrocardiograph, or a machine for diagnosing LQTS. A related method for diagnosing cardiac disorders such as LQTS includes measuring QT and QS2 during a same cardiac cycle, calculating a QT / QS2 ratio, and comparing the result to a threshold value derived from empirical data. The method may include measuring systoles both at rest and during exercise, and may be used for drug efficacy, dosage optimization, and acquired LQTS causality tests.
Owner:INTELLECTUAL ASSET MANAGEMENT
Magnetic resonance method for assesing amide proton transfer effects between amide protons of endogenous mobile proteins and peptides and tissue water in situ and its use for imaging ph and mobile protein/peptide content
Featured is an MRI / NMR methodology or process to detect amide protons of endogenous mobile proteins and peptides via the water signal. Such methods and processes can be used for the purposes of detection of pH effects and labile amide proton content of mobile proteins / peptides or content changes thereto using MRI Also featured are methods whereby assessment of determined pH effects and amide proton content or content changes and related mobile protein and / or peptide content or content changes can be used in connection with diagnosis, program and treatment of brain related disorders and diseases, cardiac disorders and diseases, and cancer and to use such methods for monitoring, detecting and assessing protein and peptide content in vivo and pathologically for any of a number of diseases or disorders of a human body, including but not limited to cancers, ischemia, Alzheimers and Parkinsons.
Owner:THE JOHN HOPKINS UNIV SCHOOL OF MEDICINE
Methods and Systems for semi-automatic adjustment of medical monitoring and treatment
ActiveUS20080097553A1Good treatment effectConvenient treatmentDrug and medicationsMedical devicesDiseaseMedical disorder
Systems and methods are described for adjusting the operation of implantable stimulation devices used to provide medical monitoring and treatment. Several hierarchical algorithms are described which operate according to conditionally obtaining a patient response to an alert signal. In one such strategy semi-automatic therapy adjustment occurs by automatically issuing patient alert messages when selected operations are to occur, and using a patient's response to the alert message that is provided within a selected time limit in order to contingently adjust therapy. Methods are also described for resolving conflicts which may occur when time information and sensed data information each indicate different patient states are occurring. Although treatment of neural and cardiac disorders is emphasized, the techniques can be applied to the monitoring and treatment of any medical disorder with an implanted device.
Owner:JOHN MICHAEL SASHA
Nucleic acid molecules and polypeptides for a human cation channel polypeptide
InactiveUS20030096249A1Increase calciumAntibody mimetics/scaffoldsTissue cultureRisk strokeNeurological disorder
The present invention relates to novel human nucleic acid molecules encoding novel human cation channels, and proteins and polypeptides encoded by such nucleic acid molecules. More specifically, the nucleic acid molecules of the invention include the novel human gene designated HBMYCNG. The proteins and polypeptides of the invention represent a novel cation channel that may be therapeutically valuable targets for drug delivery in the treatment of human diseases which involve calcium, sodium, potassium or other ionic homeostatic dysfunction, such as central nervous system (CNS) disorders, e.g., stroke, anxiety and depression, or degenerative neurological disorders such as Alzheimer's disease or Parkinson's disease, or other disorders such as cardiac disorders, e.g., arrhythmia, diabetes, chronic pain, hypercalcemia, hypocalcemia, hypercalciuria, hypocalciuria, or ion disorders associated with immunological disorders, gasto-intestinal (GI) tract disorders, or renal or liver disease.
Owner:BRISTOL MYERS SQUIBB CO
Ablation Catheters And Methods For Their Use
InactiveUS20080161803A1Reduce riskGood electrical contactSurgical instruments for heatingDiseaseCardiac disorders
Owner:RGT UNIV OF MICHIGAN
Device and method for treating disorders of the cardiovascular system or heart
InactiveUS20120323293A1Reduce rateReduce high blood pressureElectrotherapyArtificial respirationDiseaseCardiac disorders
Owner:RMX
Novel agents for preventing and treating disorders involving modulation of the RyR receptors
InactiveUS20070049572A1Improve bindingLow affinityBiocideOrganic active ingredientsSIDS - Sudden infant death syndromeDisease cause
The present invention provides novel compounds of Formula I and salts, hydrates, solvates, complexes, and prodrugs thereof. The present invention further provides methods for synthesizing compounds of Formula I. The invention additionally provides pharmaceutical compositions comprising the compounds of Formula I and methods of using the pharmaceutical compositions of Formula I to treat and prevent disorders and diseases associated with the RyR receptors that regulate calcium channel functioning in cells. Such disorders and diseases include, by way of example only, cardiac disorders and diseases, skeletal muscular disorders and diseases, cognitive disorders and diseases, malignant hyperthermia, diabetes, and sudden infant death syndrome. Cardiac disorder and diseases include, but are not limited to, irregular heartbeat disorders and diseases; exercise-induced irregular heartbeat disorders and diseases; sudden cardiac death; exercise-induced sudden cardiac death; congestive heart failure; chronic obstructive pulmonary disease; and high blood pressure. Irregular heartbeat disorders and diseases include and exercise-induced irregular heartbeat disorders and diseases include, but are not limited to, atrial and ventricular arrhythmia; atrial and ventricular fibrillation; atrial and ventricular tachyarrhythmia; atrial and ventricular tachycardia; catecholaminergic polymorphic ventricular tachycardia (CPVT); and exercise-induced variants thereof. Skeletal muscular disorder and diseases include, but are not limited to, skeletal muscle fatigue, exercise-induced skeletal muscle fatigue, muscular dystrophy, bladder disorders, and incontinence. Cognitive disorders and diseases include, but are not limited to, Alzheimer's Disease, forms of memory loss, and age-dependent memory loss.
Owner:THE TRUSTEES OF COLUMBIA UNIV IN THE CITY OF NEW YORK
System for Heart monitoring, Characterization and Abnormality Detection
A system analyzes and characterizes cardiac electrophysiological signals by determining instantaneous signal entropy for identifying and characterizing cardiac disorders, differentiating cardiac arrhythmias, determining pathological severity and predicting life-threatening events. A system for heart monitoring, characterization and abnormality detection, includes an acquisition device for acquiring an electrophysiological signal representing a heart beat cycle of a patient heart. A signal processor derives an entropy representative value of the acquired electrophysiological signal within a time period comprising at least a portion of a heart beat cycle of the acquired electrophysiological signal and provides an entropy value as a function of the entropy representative value and the time period. A comparator generates data representing a message for communication to a destination device in response to the entropy value exceeding a predetermined threshold.
Owner:PIXART IMAGING INC
Endothelin a receptor antagonists in combination with phosphodiesterase 5 inhibitors and uses thereof
InactiveUS20060205733A1Eliminate side effectsLow toxicityBiocideNervous disorderDiseasePhosphodiesterase 5 inhibitor
The invention relates generally to combination therapies comprising an endothelin A receptor (ETA) antagonist and a phosphodiesterase 5 (PDE5) inhibitor, pharmaceutical compositions comprising ETA antagonist and PDE5 inhibitor and methods of treating various disorders comprising administering an ETA antagonist and a PDE5 inhibitor. In particular, the combination therapies and pharmaceutical compositions are useful for the treatment and / or prevention of cardiac disorders such as pulmonary arterial hypertension (PAH).
Owner:ENCYSIVE PHARMA INC
System for Cardiac Status Determination
InactiveUS20110190643A1Health-index calculationEvaluation of blood vesselsCardiac disordersCardiac status
A system improves detection and diagnosis of blood pressure based cardiac function and tissue activities by analyzing and characterizing cardiac blood pressure signals (including non-invasive and invasive blood pressure, discrete values and continuous waveforms) using pressure signal variation and variability calculation and evaluation. The system combines blood pressure analysis with multi clinical related factors and parameters to detect and quantify cardiac health status and arrhythmia severity. The system determines an accurate time, location and severity of cardiac pathology and events by calculating blood pressure variability and statistical variation. The accurately and reliably identifies cardiac disorders, differentiates cardiac arrhythmias, characterizes pathological severity, predicts the life-threatening events, and supports evaluation of drug delivery effects.
Owner:SIEMENS HEALTHCARE GMBH
Expression profiling in the intact human heart
InactiveUS20030096782A1Inhibitory activityHigh activityOrganic active ingredientsPeptide/protein ingredientsCardiac disordersDisease cause
Owner:UNIV OF COLORADO THE REGENTS OF
Novel agents for preventing and treating disorders involving modulation of the RyR receptors
ActiveUS20060194767A1BiocideOrganic active ingredientsSIDS - Sudden infant death syndromeCognitive disorder
The present invention provides novel compounds of Formula I and salts, hydrates, solvates, complexes, and prodrugs thereof. The present invention further provides methods for synthesizing compounds of Formula I. The invention additionally provides pharmaceutical compositions comprising the compounds of Formula I and methods of using the pharmaceutical compositions of Formula I to treat and prevent disorders and diseases associated with the RyR receptors that regulate calcium channel functioning in cells. Such disorders and diseases include, by way of example only, cardiac disorders and diseases, skeletal muscular disorders and diseases, cognitive disorders and diseases, malignant hyperthermia, diabetes, and sudden infant death syndrome. Cardiac disorder and diseases include, but are not limited to, irregular heartbeat disorders and diseases; exercise-induced irregular heartbeat disorders and diseases; sudden cardiac death; exercise-induced sudden cardiac death; congestive heart failure; chronic obstructive pulmonary disease; and high blood pressure. Irregular heartbeat disorders and diseases include and exercise-induced irregular heartbeat disorders and diseases include, but are not limited to, atrial and ventricular arrhythmia; atrial and ventricular fibrillation; atrial and ventricular tachyarrhythmia; atrial and ventricular tachycardia; catecholaminergic polymorphic ventricular tachycardia (CPVT); and exercise-induced variants thereof. Skeletal muscular disorder and diseases include, but are not limited to, skeletal muscle fatigue, exercise-induced skeletal muscle fatigue, muscular dystrophy, bladder disorders, and incontinence. Cognitive disorders and diseases include, but are not limited to, Alzheimer's Disease, forms of memory loss, and age-dependent memory loss.
Owner:THE TRUSTEES OF COLUMBIA UNIV IN THE CITY OF NEW YORK
Regulation of type 5 adenylyl cyclase for treatment of neurodegenerative and cardiac diseases
The invention concerns pharmaceutical compositions that contain a compound or compounds that can effectively regulate the activity of Type 5 Adenylyl Cyclase and methods for treatment of neurological diseases and disorders, as well as motor function loss therefrom, as well as treatment for cardiac conditions and diseases including conditions characterized by abnormal heart rate.
Owner:NEW JERSEY UNIVESITY OF MEDICINE & DENTISTRY OF
Composition comprising xanthoceras sorbifolia extracts, compounds isolated from same, methods for preparing same and uses thereof
InactiveUS20050220910A1Preventing cerebral agingEnhance memoryBiocideSugar derivativesRheumatismHeadaches
This invention provides compositions, methods and process of producing extracts from Xanthoceras sorbifolia. The extract comprises alkaloids, coumarins, saccharides, proteins, polysaccharides, glycosides, saponins, tannins, acid, flavonoids and others. The composition can be used for treating cancer, arthritis, rheumatism, poor circulation, arteriosclerosis, Raynaud's syndrome, angina pectoris, cardiac disorder, coronary heart disease, headache, dizziness, kidney disorder, impotence and premature ejaculation; for preventing cerebral aging; for improving memory, cerebral functions; or for curing enuresis, frequent micturition, urinary incontinence, dementia, weak intelligence and Alzheimer's disease, autism, brain trauma, Parkinson's disease or other diseases caused by cerebral dysfunctions, and treating arthritis, rheumatism, poor circulation, arteriosclerosis, Raynaud's syndrome, angina pectoris, cardiac disorder, coronary heart disease, headache, dizziness, kidney disorder. This invention provides compounds comprising at least one sugar, a triterpene, such as Sapogenin, and at least one side chains at Carbon 21 and 22, such as Angeloyl groups. The compounds of the present have various pharmaceutical and therapeutic applications.
Owner:PACIFIC ARROW
Light sensitive compounds for instant determination of organ function
InactiveUS7175831B2Simple and efficient and effective monitoring of organ functionEasy to useUltrasonic/sonic/infrasonic diagnosticsBiocideDiseaseFluorescence
Highly hydrophilic indole and benzoindole derivatives that absorb and fluoresce in the visible region of light are disclosed. These compounds are useful for physiological and organ function monitoring. Particularly, the molecules of the invention are useful for optical diagnosis of renal and cardiac diseases and for estimation of blood volume in vivo.
Owner:MALLINCKRODT INC
MicroRNA-328 and application of antisense nucleotide thereof for diagnosing, preventing and curing heart diseases
The invention discloses a microRNA-328 and the application of antisense nucleotide thereof for diagnosing and controlling heart diseases; in the invention, a plurality of experiments prove that the microRNA-328 is changed and has pathopoiesia function in heavy heart diseases (atrial fibrillation, ischemia-reperfusion or myocardial fibrosis), and the antisense nucleotide AMO-328 of the microRNA-328has prevention and cure functions to the heart diseases, the microRNA-328 is used as a novel drug effect target spot, so as to finally determine and detect that the peripheral blood microRNA-328 canbe used as a novel biological marker which is used for diagnosing and preventing the heart diseases; in addition, the peripheral blood microRNA-328 expression level of a patient can be detected through fluorescent quantitative PCR and the nanometer microballoon technology enhanced by silver staining, so as to be used for diagnosing and preventing the heart diseases such as atrial fibrillation, long QT syndrome, ischemia-reperfusion or myocardial fibrosis and the like.
Owner:HARBIN MEDICAL UNIVERSITY
Use of human stem cells and/or factors they produce to promote adult mammalian cardiac repair through cardiomyocyte cell division
A method for treating a subject afflicted with a cardiac disorder, in vivo, comprising (i) producing a solution comprising media conditioned from the culture of cells, in vitro, and (ii) administering the solution of step (i) to the subject, thereby treating the cardiac disorder in the subject. Methods for determining whether an agent stimulates or inhibits myocyte proliferation.
Owner:THE TRUSTEES OF COLUMBIA UNIV IN THE CITY OF NEW YORK +1
Method for directionally differentiating multipotential stem cell in vitro into myocardial cell
ActiveCN104293730AMany connectionsDecreased frequency of calcium wavesVertebrate cellsArtificial cell constructsGerm layerHeart development
The invention provides a method for directionally differentiating a multipotential stem cell in vitro into a myocardial cell and provides a culture medium for establishing myocardial cell differentiation by means of induction in vitro under a three-dimensional suspension condition. The culture medium comprises a differential medium for induced differentiation of a multipotential stem cell into a precursor cell of mesoblast, a differential medium for differentiating the precursor cell of mesoblast into the myocardial cell and a long-term maintaining culture medium of the myocardial cell. The method provided by the invention is simple and reliable, low in cost, stable and efficient and high in safety. By adopting a suspension culture system, high-quality myocardial cells can be industrially produced without any subsequent screening and purifying steps, can be directly used for application demands of scientific research of heart development, cell therapy of heart diseases, transplanting due to cardiac trauma and drug screening, and has inestimable scientific, social and economical benefits.
Owner:昆明圆梦生命科学研究院有限公司
Composition comprising Xanthoceras sorbifolia extracts, compounds isolated from same, methods for preparing same and uses thereof
InactiveUS7727561B2Preventing cerebral agingEnhance memoryBiocideSugar derivativesRheumatismArthritis
Owner:PACIFIC ARROW
Differentiation of human mesenchymal stem cells to cardiac progenitor cells that promote cardiac repair
A method for treating a subject afflicted with a cardiac disorder, in vivo, comprises (i) inducing differentiation of a progenitor cell, in vitro, to a cardiogenic cell; and (ii) administering a therapeutically effective amount of the cardiogenic cell of step (i) to the subject, thereby treating the cardiac disorder in the subject. This invention further provides related articles of manufacture and methods.
Owner:THE TRUSTEES OF COLUMBIA UNIV IN THE CITY OF NEW YORK +1
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com